With interest we have read the comments made by Vieth and Carter in this issue of EJCN, which clearly demonstrate the general dif®culty in de®ning`an appropriate vitamin status'. This de®nition is especially dif®cult to address when we focus on the borders between`optimal status' and`subclinical de®ciency', as subjects with subclinical de®ciencies do not present with clinical symptoms per de®nition. It is increasingly recognised that subclinical de®ciency may cause disease in the long run. There is, for example, good evidence that subclinical vitamin D de®ciency, which is certainly not a synonym
D de®ciency, might be a factor in the development of osteoporosis. However, the question we need to answer is not`how much vitamin D must a healthy adult consume to be ensured of having at least a speci®c, target concentration of serum 25(OH)D 0 , since neither public health nor patient care are in the business of plasma cosmetics.
Our paper (Schaafsma et al, 2000) was a sub study on the outcome of a supplement that contained calcium, vitamin D and vitamin K, given to postmenopausal women with normal and low bone mineral density (BMD). The endpoint was BMD after one year, but in the cited paper we only discussed the encountered effects on circulating 25(OH)D and PTH (as vitamin D status indices) and percentage carboxylated osteocalcine (vitamin K index). Strictly speaking,`appropriate' evidence about vitamin D nutritional needs in adults should ultimately derive from hard clinical endpoints, ie from studies with fracture incidence as the endpoint in cases of a vitamin D ± osteoporosis relationship. In most countries soft endpoints, like a serum 25(OH)D optimised on the basis of the inverse relationship with PTH, do not get us much closer to acceptance by nutritional and medical boards. Even establishment of BMD can be considered as an example of such a soft endpoint by the hard liners amongst us. This point of view merely gives credit to randomised controlled trails (RCTs) executed according to the rules of evidence based medicine. Thereby this viewpoint directs practically all other data that becomes available, to the category`of no practical bene®t to others'. Unfortunately, this also applies to studies in which some target for 25(OH)D has been set, since without evidence to show that this target relates to a hard clinical endpoint, such a target would be as soft as all others that are apparently criticised by Vieth and Carter. It leaves us, however, with the question of who is going to embark upon these very expensive RCTs with so many parameters to control, when we do not have a single clue from soft endpoints which dosages, treatment periods, or other ®xed settings we are going to implement in these RCTs. Finally, with increasing oral vitamin D dosages, there is of course a level from which the background intake from the diet or accrual from sunlight exposure will become irrelevant. It is clear that especially the 25(OH)D winter-dip, which occurs concomitantly with a BMD-dip (Dawson-Hughes et al, 1995) , is related to osteoporosis development in the long run. When one deals with two different methods for 25(OH)D measurement, such a question may perfectly well be addressed by converting baseline levels to 100% and investigating whether there are changes with time. It is without doubt necessary to diminish the poor inter-laboratory and inter-method precision of serum 25(OH)D level detection and, if possible, to de®ne de®nitive and reference methods to improve its accuracy.
